Clinical trials: Hyperplasia
General Glucocorticoid Resistance
Mutations of Glucocorticoid Receptor in Bilateral Adrenal Hyperplasia
As the investigators observed a case of glucocorticoid mutation revealed by incidentally discovered bilateral adrenal nodular hyperplasia, it was postulated that this molecular anormality could be more frequent than previously…
- Trial name
- MUTA-GR (NCT02810496)
- Testing
- blood collection for mutation characterization
- Where
- France
- Volunteers
- 150 people
- Sponsor
- CHU de Reims
Prostatic Hyperplasia
Prospective Sexual Function Study for BPH Subjects
This is an European double-blind, placebo controlled parallel group comparison of DUODART (fixed dose combination of dutasteride 0.5mg and tamsulosin 0.4mg, one capsule daily) and placebo.
- Trial name
- NCT01777269
- Testing
- Dutasteride plus tamsulosin
- Where
- 67 sites in Australia, France and 5 more
- Volunteers
- 489 people
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia, Prostate Cancer
Digital Rectal Exam Proficiency Tool
A digital rectal exam proficiency tool, titled the 'DiRECT' was developed based on the consensus of 10 experts. The purpose of this study is to validate this tool for use in both undergraduate and graduate medical education .
- Trial name
- DiRECT (NCT02278679)
- Testing
- Digital Rectal Exam
- Where
- United States
- Volunteers
- 410 people
- Sponsor
- University of Virginia
Erectile Dysfunction, Benign Prostatic Hyperplasia
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
The purpose of this study is to evaluate the efficacy, dose-response and safety of udenafil 25 mg, 50 mg and 75 mg every day (q.d.) for 12 weeks in the treatment of lower urinary tract symptoms (LUTS) associated with benign…
- Trial name
- NCT01967251
- Testing
- Udenafil
- Where
- 8 sites in Mexico
- Sponsor
- Takeda
Prostatic Hyperplasia
Safety and Efficacy of 0.5mg Dutasteride and 0.4mg Tamsulosin Combination Once Daily for Six Months for Benign Prostatic Hyperplasia
Open-label, 6 month-treatment with the IP in all subjects. - Sample size: A total of 90 subjects will be enrolled so that among them at least 57 will complete the 6-month treatment period and evaluable for analysis.
- Trial name
- FDC114785 (NCT01673490)
- Testing
- Dutasteride/Tamsulosin
- Where
- Vietnam
- Volunteers
- 59 people
- Sponsor
- GlaxoSmithKline
Atherosclerotic Cardiovascular Disease (ASCVD), Benign Prostatic Hypertrophy (BPH)
Protective Effect of 5-Alpha Reductase Inhibitors on Atherosclerotic Cardiovascular Disease in Populations With BPH: Evidence From UK Biobank Cohort and Chinese Single Center Database Studies
To assess the impact of 5-alpha reductase inhibitors (5-ARIs) on the incidence of atherosclerotic cardiovascular disease (ASCVD) in patients with benign prostatic hyperplasia (BPH).
- Trial name
- NCT07196280
- Testing
- 5-Alpha Reductase Inhibitors
- Volunteers
- 10,000 people
- Sponsor
- Chinese PLA General Hospital
Urologic Neoplasms, Benign Prostatic Hyperplasia
Spinal Versus General Anesthesia in Open Simple Prostatectomy
Open simple prostatectomy is still performed for selected patients with benign prostatic hyperplasia, particularly in cases with large prostate volume.
- Conditions
- Urologic Neoplasms, Benign Prostatic Hyperplasia, Anesthesia
- Trial name
- NCT07643415
- Testing
- Spinal anesthesia, General anesthesia
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Hitit University
Benign Prostatic Hyperplasia, Bladder Outlet Obstruction
Thulium Laser Enucleation With Bladder Neck Incision for Small-Volume Benign Prostatic Hyperplasia
This study will evaluate the safety and effectiveness of different surgical treatments for men with small-volume benign prostatic hyperplasia (BPH).
- Conditions
- Benign Prostatic Hyperplasia, Bladder Outlet Obstruction, Lower Urinary Tract Symptoms (LUTS)
- Trial name
- ThuLEP-BNI (NCT07569874)
- Testing
- Thulium Laser Enucleation of the Prostate Combined With Bladder Neck Incision, Thulium Laser Enucleation of the Prostate, Transurethral Resection of the Prostate
- Where
- China
- Volunteers
- 932 people
- Sponsor
- Chinese PLA General Hospital
Benign Prostatic Hyperplasia
Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia
The purpose of this study was to determine the safety and effectiveness of different doses of botulinum toxin Type A in treating lower urinary tract symptoms due to benign prostatic hyperplasia.
- Trial name
- NCT00284518
- Testing
- botulinum toxin Type A, normal saline
- Where
- 11 sites in Australia, Austria and 9 more
- Volunteers
- 380 people
- Sponsor
- Allergan
Addison Disease, Adrenal Hyperplasia Congenital
Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia
The aim of this study is to compare the effects of tablet treatment, circadian and combined circadian and ultradian subcutaneous hydrocortisone infusion on steroid metabolism and tissue responses to therapy.
- Trial name
- NCT02096510
- Testing
- Solu-Cortef, Cortef
- Where
- Norway
- Volunteers
- 8 people
- Sponsor
- Haukeland University Hospital
Benign Prostatic Hyperplasia
Results of Selective Prostatic Arterial Embolization in Patients With Indwelling Urinary Catheter Due to Benign Prostatic Hyperplasia Refractory to Medical Treatment.
Background: Patients with indwelling urinary catheter for chronic retention due to obstructive BPH refractory to medical therapy are candidates for prostatectomy still considered as the gold standard of treatment.
- Trial name
- Prost-EMBOL (NCT01931605)
- Testing
- Prostatic arterial embolization using BeadBlock (Terumo)
- Where
- France
- Volunteers
- 2 people
- Sponsor
- University Hospital, Rouen
Endometrial Hyperplasia Without Atypia
MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia
To compare the efficacy of Medroxyprogesterone Acetate with dydrogesterone in patients having endometrial hyperplasia (EH) without atypia.
- Trial name
- NCT03675139
- Testing
- Medroxyprogesterone Acetate, Dydrogesterone 10 MG
- Where
- China
- Volunteers
- 471 people
- Sponsor
- Xiaojun Chen
Benign Prostatic Hyperplasia
Waterjet Prostate Ablation
Introduction Men with enlarged prostates commonly experience lower urinary tract symptoms and may go on to develop complications such as acute urinary retention (AUR).
- Trial name
- NCT03938194
- Testing
- Aquablation
- Where
- Hong Kong
- Volunteers
- 20 people
- Sponsor
- Chinese University of Hong Kong
Prostate Hyperplasia
FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH)
To establish whether the administration of FLOMAX® improves the outcome of a trial without catheter (TWOC) after an episode of acute urinary retention and to determine whether spontaneous voiding is maintained over the course of…
- Trial name
- NCT02244294
- Testing
- FLOMAX® capsules
- Volunteers
- 176 people
- Sponsor
- Boehringer Ingelheim
Intestinal LNH
Clinical Management of Childhood Intestinal Lymphoid Nodular Hyperplasia
Aim of this prospective, parallel multi-arm, randomized, clinical trial, was to compare the clinical outcome of patients Methods.We recruited children who undergone diagnostic colonoscopy in Umberto I Pediatric Department (Rome…
- Trial name
- NCT01789294
- Testing
- Mesalamine, DIET
- Where
- Italy
- Volunteers
- 270 people
- Sponsor
- Azienda Policlinico Umberto I
Endometrial Cancer, Post-Menopausal Bleeding
Pipelle® Under Ultrasound Guidance (PUG) to Investigate Post-menopausal Bleeding.
TITLE Pipelle® under Ultrasound Guidance (PUG) to investigate post-menopausal bleeding: Randomised Controlled Trial BACKGROUND Women who are suspected of having endometrial cancer (cancer of the inner lining of the womb) due to…
- Conditions
- Endometrial Cancer, Post-Menopausal Bleeding, Endometrial Hyperplasia
- Trial name
- PUG (NCT06501846)
- Testing
- Pipelle® endometrial biopsy performed under transabdominal ultrasound guidance, Pipelle® endometrial biopsy performed without ultrasound guidance
- Where
- United Kingdom
- Volunteers
- 92 people
- Sponsor
- Imperial College Healthcare NHS Trust
ECL-cell Hyperplasia, Parietal-cell Hyperplasia
Effect of Netazepide on Omeprazole-induced Changes in Chromogranin A and Gastrin
Hypergastrinaemia induced by proton pump inhibitor (PPI) treatment is reported to cause ECL-cell and parietal-cell hyperplasia, and rebound hyperacidity and dyspepsia after PPI withdrawal.
- Conditions
- ECL-cell Hyperplasia, Parietal-cell Hyperplasia, Rebound Hyperacidity, Dyspepsia
- Trial name
- NCT02620696
- Testing
- netazepide
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Breast Cancer
LY353381 in Preventing Breast Cancer in Women With Hyperplasia
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of LY353381 may be an effective way to prevent the development of breast cancer in women who have…
- Trial name
- NCT00005879
- Testing
- arzoxifene
- Where
- 2 sites in United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Benign Prostatic Hyperplasia
Safety and Feasibility of the XFLO Expander System (Mercury)
To demonstrate the safety and feasibility of the Mercury Expander system and procedure to treat patients with lower urinary tract symptoms (LUTS) secondary to urinary outflow obstruction from benign prostatic hyperplasia.
- Trial name
- EXPANDER-1 (NCT03758222)
- Testing
- XFLO Expander System
- Where
- 5 sites in Australia, Canada and 2 more
- Volunteers
- 45 people
- Sponsor
- MedeonBio, Inc.
Prostatic Hyperplasia
Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia
The purpose of this study was to determine whether the daily consumption of decaffeinated green tea catechins (Polyphenon E®) for 1 year reduces the rate of progression to prostate cancer (PCa) in men diagnosed with HGPIN or…
- Trial name
- NCT00596011
- Testing
- Polyphenon E
- Where
- 10 sites in United States
- Volunteers
- 97 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute